Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
NCT07041281Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in preeclampsia and gestational hypertension (GH) comparing Placebo: Control with Treatment: Spironolactone (2 arms). Primary endpoint: Mean 24-hour ambulatory diastolic blood pressure at 36 weeks. Started Oct 2025; status: recruiting.
02
Drugs
spironolactone
03
Conditions
preeclampsiagestational hypertension (GH)
Beyond the preview
Go deeper on NCT07041281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07041281.